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Available online 25 January 2016Bruton's tyrosine kinase (Btk) is expressed in a variety of immune cells and previouswork has demonstrated that
blocking Btk is a promising strategy for treating autoimmune diseases. Herein, we utilized a tool Btk inhibitor,
M7583, to determine the therapeutic efﬁcacy of Btk inhibition in two mouse lupus models driven by TLR7 acti-
vation and type I interferon. In BXSB-Yaa lupus mice, Btk inhibition reduced autoantibodies, nephritis, and mor-
tality. In the pristane-inducedDBA/1 lupusmodel, Btk inhibition suppressed arthritis, but autoantibodies and the
IFN gene signature were not signiﬁcantly affected; suggesting efﬁcacy was mediated through inhibition of Fc re-
ceptors. In vitro studies using primary human macrophages revealed that Btk inhibition can block activation by
immune complexes and TLR7which contributes to tissue damage in SLE. Overall, our results provide translational
insight into how Btk inhibition may provide beneﬁt to a variety of SLE patients by affecting both BCR and FcR
signaling.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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TLR71. Introduction
Bruton's tyrosine kinase (Btk) is expressed in a large variety of im-
mune cells including monocytes, macrophages, basophils, mast cells,
and B cells. Btk regulates signaling downstream of the B cell receptor
(BCR) and Fc receptors (FcR) and may also play a role in toll-like recep-
tor (TLR) signaling [1,2]. Previous studies using Btk deﬁcient mice and
Btk inhibitors have demonstrated that loss of Btk activity can ameliorate
disease in animal models of autoimmune disorders including rheuma-
toid arthritis [3] and systemic lupus erythematosus (SLE) [4–7]. Conse-
quently, Btk is considered a promising drug target for treatment of these
diseases.
SLE is an extremely heterogeneous disease that manifests with a
wide variety of symptoms including fatigue, rash, arthritis, nephritis,
and neurological dysfunction. The pathogenesis and etiology of the dis-
ease are also diverse with patients showing different environmental ex-
posures, genetic predispositions, autoantibody proﬁles, and various
cellular dysfunctions. Given the high degree of heterogeneity in SLE, itl-like receptor 7; BCR, B cell re-
atosus; IFN, interferon; FACS,
mofetil.
. Bender).
. This is an open access article underwould be decidedly beneﬁcial to use preclinical animalmodels that rep-
resent different patient populations to learn how inhibition of a certain
pathway or target affects disease. One drug target of interest is Btk, as
this enzyme regulates signaling in several pathways relevant to autoim-
mune disease. Btk inhibitors have previously been tested and found to
be efﬁcacious in the NZB/W [4,6], MRL/lpr [7], and B6.Sle1 [5] mouse
models of SLE. However, thesemodels do not recapitulate all the differ-
ent subsets of lupus patients, and therefore there is a gap in knowledge
as to how Btk inhibitionmay affect disease driven by TLR activation and
type I interferon (IFN). Thus, we wished to test the potential for Btk in-
hibition to provide therapeutic beneﬁt in SLE mouse models that are
more TLR7-driven and have a higher IFN involvement.
Substantial evidence exists implicating TLR7 [8] and IFN [9] in the
pathogenesis of human lupus and anti-IFN agents are currently being
evaluated in clinical trials [10]. The IFN gene signature, which serves
as a marker for high IFN activity, has been shown to be elevated in as
much as 50% of all lupus patients. Polymorphisms in these pathways
have been found to increase the risk for developing SLE [11] and females
have demonstrated higher sensitivity to TLR7 activation [12], consistent
with their greater propensity for SLE development. Additionally, there
have been correlation studies of high IFN in SLE patients and those
with high IFN are likely to develop more severe disease [10]. However,
these patients have not been well represented in prior preclinical stud-
ies testing Btk inhibition and little is known about how Btk blockade
might affect TLR7 and IFN-driven disease processes.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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models of lupus were utilized to test the potential efﬁcacy of Btk inhibi-
tion for treating TLR7 and IFN-driven SLE. Previous results in related
models have suggested that genetic Btk deﬁciency may affect disease
in the context of Yaa duplication [13] or after pristane injection [14]
and we wished to determine if a reduction in Btk activity by treatment
with a pharmacological inhibitor could have similar efﬁcacy. BXSB-Yaa
mice have a duplication of the Yaa locus, which results in increased ex-
pression of TLR7 and spontaneous development of disease [13,15]. The
lupus-like disease that develops is characterized by production of auto-
antibodies, lymphoid hyperplasia, and nephritis which leads to early
mortality. Proteinuria is an early marker of nephritis in these mice and
histological analysis of kidneys reveals evidence of severe glomerulone-
phritis. In the pristane-DBA/1 model, DBA/1 strain mice are injected in
the peritoneum with the hydrocarbon pristane which induces disease
development. The disease has mechanistically been characterized as
highly TLR7 and IFN dependent [16] and involves generation of autoan-
tibodies and development of arthritis [17]. The arthritis that develops is
autoantibody-mediated and has similarities to that of SLE patients as it
manifests as a mild erosive disease [18]. The pristane model is one of
the very few mouse lupus models that has been demonstrated to dis-
play a robust IFN gene signature [17] and it thereforemay be particular-
ly relevant as a model for IFN high lupus patients. The autoantibody
production in pristane-DBA/1 mice is biased toward reactivities against
RNA-binding proteins such as RiboP and SmRNP, more so than against
dsDNA or other DNA associatedmolecules, similar to what has been ob-
served for SLE patients with high IFN signatures as they demonstrate a
biased increase in RNA-binding reactivities [19,20]. Even though these
two models both are highly TLR7 dependent, they may represent dis-
tinct subsets of lupus as they have different pathogenesis, autoantibody
proﬁles, and end organ diseasemanifestations. Thus, utilizing these two
different models allows for interrogating the effect of Btk inhibition on
TLR7-driven disease with a variety of readouts.
In our studieswe utilized a smallmolecule Btk inhibitor, M7583, as a
tool to assess the potential for Btk inhibition to treat lupus in the BXSB-
Yaa and pristane-DBA/1mouse lupusmodels.We ﬁrst present a charac-
terization of the compound to demonstrate its suitability as an effective
Btk speciﬁc inhibitor suitable for in vivo use, and then demonstrate the
efﬁcacy of Btk inhibition for treatment of disease in the twomodels. We
also performed studies using FACS, gene expression analysis, and
human immune cells to further characterize the mechanism of action
of Btk inhibition efﬁcacy and how this might translate in humans. This
work demonstrates the potential for Btk inhibitors to provide beneﬁt
to lupus patients of different disease subsets and provides mechanistic
insight as to how Btk inhibitors may affect multiple immunological pro-
cesses mediating disease pathogenesis.
2. Methods
2.1. Mouse lupus models
All procedures using animals were performed in accordance with
the EMD Serono Institutional Animal Care and Use Committee
(IACUC) and all local and national laws and regulations regarding ani-
mal care. Female DBA/1mice used for pristanemodel studies were pur-
chased from Jackson Labs. To induce disease development DBA/1 mice
were injected with 0.5 ml of pristane (Sigma) i.p. at 11–12 weeks of
age. Beginning at 2 months after pristane injection mice were fed
chow formulated with M7583 at a concentration of 25 mg of com-
pound/kg of chow. The consumption of chow was measured weekly
and bodyweightswere recorded and these two valueswere used to cal-
culate the dose of compound received per mouse which averaged
3.35 mg/kg over the course of the study. Mice were also fed chow for-
mulated with mycophenolate mofetil (MMF) (Selleck Chemicals) at a
concentration of 500 mg/kg of chow which resulted in a dosage of
63.6 mg/kg. Vehicle groupmicewere fed chow of the same diet (HarlanTeklad 2018) without any added compounds. Chow formulations were
made by Research Diets, Inc. At 6 months after pristane injection mice
were euthanized via CO2 asphyxiation and blood was collected via the
vena cava. Spleens were collected and split in half for FACS analysis or
gene expression analysis, and paws were preserved in formalin for his-
tology analysis.
Male BXSB-Yaa mice were purchased from Jackson Labs and at
9 weeks of age treatment was initiated using the same formulated
chows described above fed to theDBA/1mice. Based on chow consump-
tion and bodyweights, BXSB-Yaamice received on average 3.7mg/kg of
M7583 and 74.4 mg/kg of MMF. At 20 weeks of age mice were eutha-
nized via CO2 asphyxiation and blood was collected via the vena cava.
Spleenswere collected and split in half for FACS analysis or gene expres-
sion analysis, and kidneys were preserved for histology analysis.
2.2. Arthritis and nephritis assessments
Arthritis development in pristane-injectedmicewasmonitored over
time and clinical scores were assigned based on inﬂammation and
swelling similar to a scoring system previously detailed [21]. Mice
were scored on a scale of 0–4 per pawwith 4 being the most severe ar-
thritis, and scores from all 4 paws were summed for a total score. At the
conclusion of the study paws were removed, ﬁxed in formalin and
shipped to HistoTox Labs where they were processed for toluidine
blue staining and scored for histological evidence of damage by a
trained pathologist. For monitoring of proteinuria in BXSB-Yaa mice,
urinewas collected bybladdermassage in themorning on 2 consecutive
days and the sampleswere pooled. The levels of albumin and creatinine
in the urine were determined using the Advia 1800 clinical chemistry
analyzer (Siemens). The urinary albumin-to-creatinine ratio (UACR)
was calculated as the ratio of milligrams of albumin per gram of creati-
nine per deciliter of urine. At the conclusion of BXSB-Yaa studies kid-
neys were collected, ﬁxed in formalin and shipped to HistoTox Labs
where they were processed for hematoxylin and eosin staining and
scored for histological evidence of damage by a trained pathologist.
The scoring system usedwasmodiﬁed from a previously published sys-
tem [22] and evaluates kidney sections based on glomerular crescents,
protein casts, interstitial inﬂammation, and vasculitis and a total histol-
ogy score is obtained based on a composite score of these parameters.
2.3. In vitro assays
The potency for M7583 against Btk was determined using puriﬁed
rBtk (Carna Biosciences). The Btk protein was diluted in buffer to a
ﬁnal of 0.05 ng/μl with 75 μM ATP and 1 μM of the KinKDR peptide
FITC-AHA-EEPLYWSFPAKKK-NH2 (Tufts Core Facility, BostonMA). Var-
ious concentrations of M7583 were also included. Reactions were per-
formed at 25 C for 90 min and halted by addition of stop solution
containing 0.5 M EDTA. Plates were then read on the Caliper LabChip
3000 (Caliper Life Sciences) and the data was loaded into GeneData
Screener for generation of IC50 curves.
Kinase selectivity forM7583was determined in the Kinase Proﬁler™
screening panel (EMD Millipore) that tested the inhibitory activity of
the compound at 1 μM against 270 kinases. The biological selectivity
of M7583 was assessed in vitro using primary human cells with
BioMap® proﬁling by BioSeek Inc. The activity of the compound was
assessed using a concentration range of 1 nM to 1 μM in 12 different pri-
mary cell co-culture assay systems according to previously published
methods [23].
The ability of M7583 to block FcR signaling was determined using
basophils in whole blood. Human blood was collected with citrate as
an anticoagulant and transferred to 96 well plates. Blood was pre-
treated for 30 min at 37 °C with dilutions of M7583 before activation
with anti-IgE (BeckmanCoulter) added to a ﬁnal of 2 μg/ml and incubat-
ed at 37 °C for 5min. After activation, cells were stained for 15minwith
anti-CD63-FITC (BD Biosciences) and then PBS-EDTA (20 mM) was
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dehyde prior to FACS analysis. The MFI for CD63 expression was deter-
mined after ﬁrst gating for CD123+HLA-DR− cells using the Canto II
instrument (BD Biosciences). The ability of M7583 to block BCR signal-
ingwas determined using B cells inwhole blood. Human bloodwas col-
lected with citrate as an anticoagulant and transferred to 96well plates.
Blood was pre-treated for 60 min at 37 °C with dilutions of M7583 be-
fore activation with goat anti-human IgM (Fab′)2 (Dianova) added to
a ﬁnal of 20 μg/ml and incubated at 37 °C overnight. After activation,
cells were stained for 45 min with anti-CD69-APC (BD Biosciences)
and anti-CD19-PerCP-Cy5.5 and then lysed using FACS lysis solution
(BD Biosciences) and resuspended in PBS prior to FACS analysis. FACS
analysis was performed on the Canto II instrument and cells were ﬁrst
gated on CD19 and the percent of CD19+ cells that were also positive
for CD69 was determined.
Human PBMCswere isolated frombuffy coat preparations of healthy
donors (New York Blood Center) using Ficoll Paque Plus (GE Health Sci-
ences) according to the manufacturer's instructions. Monocytes were
puriﬁed by adherence to plastic for 90min and subsequently differenti-
ated to macrophages by culture with 100 ng/ml GM-CSF
(Sargramostim, Sanoﬁ) in RPMI 1640 (Gibco) containing Pen/Strep
and 10% heat inactivated fetal bovine serum (Corning). Complexes of
human IgG-biotin (Jackson ImmunoResearch) and streptavidin-coated
beads (0.3 μm in size from Thermo Scientiﬁc) were formed by mixing
the two and gently rotating for 1 h at 4 °C. Beads were also mixed
with the same IgG, but non-biotin tagged as a control. After rotation,
the beads were washed once to remove unbound IgG and the com-
plexes were then added to cells in RPMI 1640 containing 10% ultra-
low IgG FBS and incubated at 37 °C. After 24 h the media was removed
for measurement of TNF-α production by ELISA (R&D Systems).
PBMCs were stimulated to produce IFN by treatment with a puriﬁed
human anti-RNP IgG preparation. Anti-RNP (Immunovision Inc.) was
combined with necrotic lysate from HEK cells subjected to 4 cycles of
free thawing to −80 °C. The anti-RNP was combined with the lysate
at a ﬁnal concentration of 5% in media, and as a control lysate was also
pre-treated with 1 μg/ml RNAse (Fisher) for 30 min at 37 °C to demon-
strate the RNA dependency of the stimulation. PBMCswere treatedwith
the anti-RNP complexes in media (RPMI 1640 + 10% FBS + pen/
strep + L-glut) at a concentration of 2.5 × 105cells/ml in a total volume
of 200 μl in 96 well plates for 16 h at 37 °C. After incubation, cell super-
natant was collected and 150 μl was applied to HEK293 ISRE-luc report-
er cells (generated in house) and incubated for 6 h. Afterwards, media
was removed and 50 μl of Steady-Glo® luciferase substrate was added
and the cells were incubated for 10 min and the luciferase signal was
quantitated on the Inﬁnite M1000 Pro plate reader (Tecan).
2.4. Pharmacokinetics and Btk occupancy
C57BL/6mice (Charles River Labs)were used to determine the phar-
macokinetics and pharmacodynamic activity ofM7583.M7583was for-
mulated in 20% Kleptose HPB (Roquette) in 50 mM Na-Citrate buffer
pH 3.0. Compound was administered by oral gavage, and at timepoints
after dosing blood was collected via the vena cava into tubes treated
with heparin as an anti-coagulant. A portion of the blood was used for
determination of Btk occupancy and the remainder was centrifuged
for isolation of plasma which was used for measurement of compound
concentrations by LC–MS.
Btk occupancy was determined using a biotinylated-probe
(MSC2527393) which is a Btk inhibitor that competes with M7583 for
binding to the active site on Btk. This methodology is similar to a previ-
ously reported assay for measuring occupancy [24]. Brieﬂy, 80 μl of
blood collected from mice was aliquoted into tubes and the red blood
cells were lysed by addition of 800 μl of RBC lysis buffer (RocheDiagnos-
tics). Cells were then washed once with 400 μl of RBC lysis buffer and
the remaining white cells were incubated in RPMI 1640 with 1 μM of
the biotinylated probe for 1 h at 37 °C. The cells were then lysed bythe addition of 120 μl of MPER lysis buffer (Pierce) and used in a
streptavidin-capture ELISA to assess probe binding to Btk.
To perform the ELISA Btk occupancy assay streptavidin-coated 96
well plates (R&D Systems) were blocked with blocking buffer
(PBS+ 2% BSA) 200 μl/well at room temperature for 1 h. After blocking,
plates were washed once 200 μl/well with washing buffer (PBS/0.05%
tween 20) and then 100 μl/well of standards or probe-treated cell lysate
were added per well of the plate diluted in PBS + 1 mg/ml BSA and in-
cubated for 2 h at room temperature with gentle shaking. Recombinant
human Btk (Carna Biosciences) previously treated with the probe was
used to construct a standard curve. Plates were then washed
3 × 200 μl/well and a rabbit anti-Btk antibody (Pierce) was added
100 μl/well at 1 μg/ml in PBS and plates were incubated for 1.5 h with
gentle shaking. Plates were then washed 3 × 200 μl/well and a donkey
anti-rabbit HRP-tagged antibody (Jackson ImmunoResearch) was
added 100 μl/well at 0.16 μg/ml in PBS and plates were incubated for
1.5 h. Plates were next washed 3 × 200 μl/well and TMB substrate (BD
Biosciences) was added 100 μl/well. After sufﬁcient color development
the reaction was halted by the addition of 1 N H2SO4 (Sigma). Plates
were immediately read at 450 nm using a SpectraMax®M5microplate
reader (Molecular Dynamics).
2.5. Autoantibody assays
Autoantibodies were measured in mouse plasma samples using a
custom manufactured 5-plex Meso Scale Discovery (MSD) plate for as-
sessment of ﬁve different autoantibodies: anti-dsDNA, anti-histone,
anti-Ro/SSA, anti-Sm/RNP, and anti-RiboP. Standard binding plates
were coated by MSD with activated calf thymus DNA, histones puriﬁed
fromchicken RBCs, Ro/SSA frombovine spleen, Sm/RNP from calf spleen
or thymus, and RiboP from bovine thymus. DNAwas coated at 50 μg/ml
and was from Sigma while all other antigens were from Immunovision
and coated at 50 U/ml except for histones which was at 50 μg/ml. To
perform the assay, plates were blocked overnight with PBS + 5% BSA
(Sigma) and then washed once with washing buffer (PBS + 0.05%
tween 20). Plasma samples were diluted 1:100 with PBS + 0.5% BSA
and loaded 100 μl/well. Plasma samples from MRL/lprmice with high
autoantibody titers were pooled to create a standard which was used
for all assays. Serial dilutions of the standard were prepared to create
a standard curve to allow for quantitative comparison of the lupus
study plasmas and values were expressed as autoantibody units per
ml of plasma (U/ml). The most concentrated standard was arbitrarily
assigned a value of 100 U/ml. Plates were incubated with samples and
standards for 2 h with gentle shaking and were then washed
3 × 200 μl/well. An anti-mouse-SULFO-TAG antibody (MSD) was then
added at a 1:500 dilution and incubated for 2 h with gentle shaking.
Plates were then washed 3 × 200 μl/well and 2× Read Buffer (MSD)
was added and the plateswere immediately read on theMSDSector Im-
ager 600 and data was processed using the MSD Discovery Workbench
2.0 software.
2.6. FACS analysis
At the conclusion of studies micewere euthanized and spleens were
collected as described above. One half of each spleen was added to 5ml
of ice cold PBS with 2% heat inactivated fetal bovine serum (HIFCS)
(Corning). Homogenization was performed using the gentleMACS
Octo Dissociator (Miltenyi Biotech). Red blood cells were lysed using
ACK lysis buffer (Lonza) and the remaining splenocytes were washed
and resuspended in PBS containing 2% HIFCS. Splenocytes (1 × 106 per
well in 96 well plates) were incubated with anti-CD16/CD32 antibody
(BD Biosciences) to block IgG-Fc receptors, followed by 20 min incuba-
tion with antibodies against cell surface markers or control IgG. Anti-
bodies used for staining were all from BD Biosciences and were: anti-
CD16/CD32 (2.4G2), PerCP-Cy™5.5-conjugated anti-B220 (RA3-6B2),
BV421-conjugated anti-CD138 (281-2), PE-conjugated anti-CD69
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CD38 (90/CD38), PE-CF594 conjugated-anti-CD11c(HL3), APC-H7-con-
jugated-anti-CD8a (53-6.7), BV510-conjugated anti-CD11b (M1/70),
BV650 conjugated anti-CD4 (GK1.5), AlexaFlor700-conjugated anti-
Ly6C (AL-21), ratIgG2a (R35-95), rat IgG2b (R35-38), rat IgM (R4-22),
hamster IgG (A19-3). After staining, cells were washed twice in PBS
containing 2% HIFCS and were evaluated on a LSR Fortessa X-20 (BD)
and the percentage of cells positive for different markers was analyzed
using FlowJo software (Tree Star, Inc.).
2.7. Gene expression analysis
Gene expression analysis was performed using the NanoString plat-
form. At the conclusion of studies mice were euthanized and spleens
and kidneys were ﬂash frozen in liquid nitrogen. Blood was collected
and 100 μl was preserved in RNAlater (Qiagen) at room temperature
and then frozen to−80. Kidneys and spleens were later thawed and
added to RLT buffer (Qiagen) and then homogenized in M tubes
(Miltenyi) using the gentleMACS Octo Dissociator and program
RNA_01. After homogenization, RNA was puriﬁed using the Qiagen
RNeasy Mini Kit. The RNeasy Protect Animal Blood System was used
for bloodRNA isolation after sampleswere preserved in RNAlater. A cus-
tom 50 gene panel was designed for NanoString analysis and included
45 disease relevant genes for interrogation and 5 housekeeping genes
for normalization (see Supplemental Table 2 for gene list). Puriﬁed
RNA samples were hybridized overnight to gene speciﬁc reporter
probes at 65 °C and analyzed using the NanoString Prep Station and
nCounter instruments according to the manufacturer instructions with
100 ng of RNA as input.
3. Results
3.1. M7583 is a potent and selective Btk inhibitor
M7583 is an irreversible Btk inhibitor [25,26] and in these studies
we have utilized it as a tool to advance the understanding of the
potential for Btk inhibition to treat a subset of lupus patients not
modeled in previous preclinical studies. Before usage in disease
model studies, a characterization of the compound was performed
to qualify its selectivity, potency, and suitability as a speciﬁc Btk
inhibitor and in vivo tool.
M7583 covalently reacts in the active site of Btk and thus perma-
nently prevents catalysis. Using puriﬁed recombinant protein it was
demonstrated that the compound is a potent inhibitor of Btk and has
an IC50 of 1.48 nM (Supplemental Fig. 1A) for the puriﬁed enzyme.
M7583was next tested for potency in cellular assays of BCR and FcR sig-
naling. The compoundwas found to completely and potently block BCR
activation (Supplemental Fig. 1B) with an IC50 of 45.75 nM and also
inhibited FcR activation in basophils (Supplemental Fig. 1C) with an
IC50 of 1.01 μM. The potency was less in basophils than for inhibition
of the BCR, but it has been reported with other Btk inhibitors as well
that there are some differences in potency for different cell types and
readouts [27].
As M7583 is an irreversible Btk inhibitor that permanently
occupies the active site, it has the potential to have prolonged inhib-
itory activity given the long half-life of the Btk protein [24]. The
duration of Btk occupancy and timecourse for clearance of M7583
in mice was determined after administration of a single oral dose.
Btk occupancy was measured in an assay using a biotin-tagged
probe and streptavidin-capture ELISA similar to an assay previously
described [24]. It was found that dosing mice with M7583 led to a
high degree of Btk occupancy and the inhibitory activity persisted
for several days, long after the compound had been cleared from
the circulation (Supplemental Fig. 2). More detailed characterization
of the pharmacokinetics of the compound revealed that it has sufﬁ-
cient bioavailability (16%) with a relatively short half-life (45 min),and moderate volume of distribution (0.87 L/kg) in mice. These
results indicate that M7583 treatment of mice will result in a robust
sustained inhibition of Btk.
The compound was tested for selectivity against 270 kinases using
theKinase Proﬁler Panel (EMDMillipore). At a compound concentration
of 1 μM the compound showed an excellent selectivity proﬁle with only
6 other kinases inhibited greater than 50% (ZAP-70, Blk, Bmx, Txk, Itk,
SGK) (Fig. 1A and Supplemental Table 1). Although there are numerous
other kinases the compoundwas not tested against, the kinase proﬁling
results reveal the compound targets a limited number of kinases other
than Btk and should have a limited number of off-target effects. The
speciﬁcity for the compound against different disease relevant path-
ways and processeswas determined using a BioSeek BioMAP® proﬁling
panel which tested the compound in 12 different co-culture systems
using 7 different primary human cell types (Fig. 1B). In the 12 different
assay systems the compound only showed activity in the B cell/T cell in-
teraction system,which utilizes anti-IgMB cell activation andmild T cell
stimulation to mimic T cell dependent B cell activation and class
switching. The speciﬁcity shown in the BioMap panel is another indica-
tion of the selectivity of the compound for Btk, as aside from the B cell/T
cell systemnone of the other assay systems are likely Btk-regulated pro-
cesses. Overall, these in vitro and cellular results demonstrate that
M7583 is a highly potent and selective Btk inhibitor that can block
both BCR and FcR signaling and is qualiﬁed as a pharmacological tool
for in vivo studies.3.2. Efﬁcacy of Btk inhibition in mouse lupus models
To assess the potential of Btk inhibition as an effective SLE treat-
ment strategy, M7583 was tested in the BXSB-Yaa and pristane-
DBA/1 mouse lupus models for efﬁcacy. The BXSB-Yaa and
pristane-DBA/1 models are both driven by TLR7 activation, but are
different in that they have dissimilar disease manifestations. Testing
candidate SLE therapeutic strategies in multiple models is informa-
tive as the disease is heterogeneous and different models may repre-
sent disparate patient populations.
BXSB-Yaa mice develop severe nephritis and the resulting kidney
disease can lead to early mortality, similar to the disease suffered by
lupus nephritis patients. When BXSB-Yaa mice were treated with
M7583 or the standard of care reference drug mycophenolate mofetil
(MMF), it was found that both compounds led to a signiﬁcant reduction
in proteinuria (Fig. 2A, B). This reduction in nephritis resulted in much
improved survival for mice treated with either compound (Fig. 2C). To
conﬁrm that proteinuria and early mortality were a result of inﬂamma-
tion and glomerulonephritis, and compound treatment was affecting
this pathology, kidneys were analyzed by histology and this analysis
showed that treatment did in fact reduce kidney damage (Fig. 2D, E).
The histology results support the conclusion that the improvement in
survival with either Btk inhibition or MMF treatment was likely due to
a decrease in kidney damage.
DBA/1 mice injected with pristane develop arthritis that is clinically
visible and also detectable upon histological evaluation of toluidine blue
stained paw sections. This pathology is analogous to the rheumatic
symptoms experienced by many SLE patients. Inhibition of Btk with
M7583 treatment in this model led to a signiﬁcant reduction in clinical
signs of arthritis and showed greater efﬁcacy than MMF (Fig. 3A, B).
Dosing of mice with M7583 led to a signiﬁcant reduction in arthritis
scores and there was a mild therapeutic effect withMMF as well. Histo-
logical analysis of the paws showed that the arthritiswasmainly inﬂam-
matory in nature and minimal bone destruction was noted. The
histological analysis of the paws of these mice conﬁrmed the anti-
arthritic activity of Btk inhibition as pathology in the joints was signiﬁ-
cantly reduced with M7583 treatment (Fig. 3C). Thus, in both models
there was a reduction in clinical disease (nephritis and arthritis) with
M7583 treatment and inhibition of Btk.
Fig. 1.M7583 kinase and cellular selectivity. Selectivity of M7583was determined in theMillipore Kinase Proﬁler screen and shown are the results in a kinase tree formatwith the activity
of themolecule at 1 μMagainst individual kinases displayed by the size of the red circle (A). The speciﬁcity ofM7583was tested by BioSeek in a BioMAP® panel of 12 assays that represent
different disease relevant systems/pathways using 7 different human cell types (B). The compound was tested at concentrations ranging from 1 nM to 1 μM.
69A.T. Bender et al. / Clinical Immunology 164 (2016) 65–773.3. Effects on autoantibody levels in lupus mice
After observing a reduction in endorgan damagewith Btk inhibition,
we explored themechanism bywhichM7583 reduced disease. Autoan-
tibodies are used both clinically and preclinically as a disease marker
and readout for B cell activation. They may also be useful for patient
stratiﬁcation and subsetting. At the conclusion of BXSB-Yaa and
pristane-DBA/1 lupus studies, autoantibodies weremeasured in plasma
samples using a custommultiplex assay on the MSD platform that tests
for 5 different auto-reactivities (anti-dsDNA, anti-histones, anti-Ro/SSA,
anti-Sm/RNP, and anti-RiboP). In BXSB-Yaa studies (Fig. 4A) mice were
sampled just before the start of treatment at 9 weeks of age (Pre-treat-
ment) via a submandibular bleed and also at the end of the study at
20 weeks of age (Post-treatment). It was found that mice of this strain
display elevated titers of anti-dsDNA, anti-histone, and anti-Ro/SSAwhich increase with time. Anti-Sm/RNP and anti-RiboP autoantibodies
were not detectable in these mice. The increase in titers of autoanti-
bodies was signiﬁcantly blocked by inhibition of Btk with M7583.
There was a trend toward reduction in autoantibody titers with MMF
treatment as well, but the effect did not reach statistical signiﬁcance
for any of the auto-reactivities.
In the Pristane DBA/1 model (Fig. 4B) there was an increase in anti-
dsDNA, anti-histones, and anti-Ro/SSA with disease (Veh vs PBS), but
the increase in titers was modest in comparison to the elevation seen
in the BXSB-Yaamice. In contrast, pristane-DBA/1 mice had a large in-
duction of anti-Sm/RNP and anti-RiboP (data not shown) autoanti-
bodies. Treatment of pristane-injected DBA/1 mice with M7583
reduced levels of anti-dsDNA, anti-histones, and anti-Ro/SSA, but not
anti-Sm/RNP. MMF treatment did not signiﬁcantly impact titers of any
of the autoantibodies. There have previously been reports indicating
Fig. 2. Efﬁcacy of Btk inhibition in the BXSB-Yaamouse lupus model. Beginning at 9 weeks of age BXSB-Yaa mice were dosed with M7583 (M7583) or mycophenolate mofetil (MMF) via
formulated chow and vehicle group mice were fed normal chow (Veh). Urine samples were collected over time and proteinuria was determined by measuring the urinary albumin to
creatinine ratio (UACR) (A and B) and the values for mice at the 20 week timepoint are shown individually (B). Treatment with either M7583 or MMF increased survival (C).
Histological analysis of kidneys collected at 20 weeks of age was performed to evaluate nephritis and results are presented as a Histology Score which is a composite assessment of
several parameters (D). Young 9 week of age pre-diseased (Pre) mice kidneys were collected and served as a healthy control group. Representative pictures of the histological results
are shown (E). Results presented are a compilation of 2 separate studies. For survival, **signiﬁcantly different from Veh p b 0.01 or *signiﬁcantly different from Veh p b 0.05 (Mantel–
Cox test). For UACR, **signiﬁcantly different from Veh p b 0.01 or *signiﬁcantly different from Veh p b 0.05 (Kruskal–Wallis, Dunn's). For Histology score, **signiﬁcantly different from
Veh p b 0.01 (ANOVA, Dunnett's).
70 A.T. Bender et al. / Clinical Immunology 164 (2016) 65–77that the cell populations responsible for production of anti-RNA binding
reactivitiesmay be different from those producing anti-dsDNAand anti-
histones. It has been suggested that long-lived plasma cells produce
anti-RNA reactivities while plasmablasts are the source of anti-dsDNA
and other auto-reactivities [28]. Furthermore, the elimination of cells
producing anti-RNA binding reactivities is more challenging [28] and
may explain our ﬁnding that MMF and Btk inhibitor treatment did not
reduce anti-RNA binding reactivities. However, it is unclear which sub-
set of autoantibodies is responsible for disease pathology as levels of
plasmablasts and anti-dsDNA titers do tend to trackwith ﬂare in SLE pa-
tients whereas the levels of RNA-binding reactivities remain more con-
stant [29]. Also, in pristane treatedmice there has only been reported to
be a small increase in autoantibodies against connective tissue antigens
[30] which typically mediate arthritis development in RA, and we did
not detect a major increase in anti-collagen II titers in our pristane-
DBA/1mice (data not shown). Overall, the autoantibody results demon-
strate an ability for Btk inhibition to affect B cells and ultimately
antibody-secreting cells to reduce autoantibody production. However,the effect seems to be more signiﬁcant in the BXSB-Yaa model and
greater against anti-dsDNA and anti-histone autoantibodies compared
to RNA-binding reactivities such as anti-Sm/RNP.
3.4. Cell populations affected by Btk inhibition in lupus mice
To try to gain greater insight intowhich cell types Btk inhibitionmay
be affecting, FACS analysis was performed on splenocytes from lupus
model mice. Spleens from BXSB-Yaamice (Fig. 5A) were analyzed for
percentages of B cells (B220+) and T cells (CD4+ and CD8+) expressing
CD69.With bothM7583 andMMF treatment there was a reduction in B
and T cells expressing CD69, indicating the compounds had reduced ac-
tivation of these cell populations. Furthermore, plasma cells (B220+-
CD38INTCD138HI) were signiﬁcantly reduced with M7583 treatment.
This reduction in plasma cells could explain the decreased levels of au-
toantibodies seen with compound treatment. There was no change in
total percentages of B220+ and CD4+ cells with compound treatment,
but there was a slight elevation of CD8+ cells with both M7583 and
Fig. 3. Efﬁcacy of Btk inhibition in the pristane DBA/1 mouse lupus model. Mice were dosed starting at 8 weeks after pristane injection with M7583 (M7583) or mycophenolate mofetil
(MMF) via formulated chow and vehicle group mice were fed normal chow (Veh) while mice not injected with pristane served as non-diseased controls (Ctl). Mice were scored for
observable signs of arthritis over time (A) and the maximum arthritis score achieved for each mouse is shown (B). At the end of the study, 24 weeks after pristane injection,
histological damage in the T-blue stained paws was scored (C). Representative pictures of the histological results are shown (D). Results presented for the timecourse are
representative of one study and the other results are a compilation of 2 separate studies and aremeans± SEM. **Signiﬁcantly different from Veh p b 0.01 or *p b 0.05 (ANOVA, Dunnett's).
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formed on spleens at the conclusion of pristane-DBA/1 studies (Fig. 5B).
M7583 increased the percentage of B cells expressing CD69, but did not
have an impact on T cell CD69 expression. There was also a dramatic re-
duction in B220+CD38INTCD138HI cells with M7583 treatment in the
pristane-DBA/1 model. MMF had a negligible effect on these cell popu-
lations. The interpretation of the spleen FACS analysis results in the
pristane-DBA/1 model is confounded by the fact that disease may be
more driven by cell activation in the peritoneum,where pristane gener-
ates lipogranulomas that function as ectopic lymphoid tissue and are a
major site of IFN and autoantibody production [16]. However, there
seems to be a reduction in B cell activation and numbers of plasma
cells with Btk inhibition in both models as is to be expected given the
major dependence of BCR signaling on Btk.
3.5. Gene expression analysis of lupus mice
To learnmore aboutwhich pathways and processes are contributing
to disease in the two models and how they are affected by Btk inhibi-
tion, gene expression in the blood and different organs of lupus mice
was measured by NanoString analysis. At the conclusion of BXSB-Yaa
and pristane-DBA/1 studies, blood, spleens, and kidneys were collectedand RNA was isolated and subsequently analyzed on the NanoString
platform using a 50 gene panel comprised of markers for various cell
types, inﬂammation, and tissue damage (see gene list in Supplemental
Table 2).
Gene expression analysis was performed on BXSB-Yaamice (Fig. 6)
from the vehicle group, M7583 treated group, and young healthy mice
which served as a control group (Ctl). Fold changes in expression from
the control group were calculated to determine which genes were in-
creased with disease (Veh vs Ctl) and which genes were subsequently
affected by Btk inhibitor treatment (M7583 vs Veh). There were a
large number of genes found to be statistically changed with disease
in the kidney. The majority of these genes were markers of inﬁltrating
immune cells (i.e. CD4, ITGAM, CD68, PSMB9) or inﬂammatory cytokine
genes (i.e. CCL2, TNF, CXCL1). The induction of these genes was greatly
reduced by Btk inhibitor treatment. In the spleen, there were changes
in many B cell and plasma cell markers. Interestingly, in diseased
mice, increases in the plasma cell markers SDC1 (CD138) and XBP1
were noted while decreases in general B cell markers such as EBF1,
BANK1, and MS4A1 (CD20), were found. Similarly, changes in B cell
numbers and plasma cell proportions have also been found in human
SLE [31–33]. Btk inhibitor treatment reversed these changes and actual-
ly decreased SDC1 and XBP1 expression to below the level of the Ctl
Fig. 4. Autoantibody production in lupus mice is reduced by Btk inhibition. Lupus mice were treated with M7583 (M7583) or mycophenolate mofetil (MMF) via formulated chow and
vehicle group mice were fed normal chow (Veh). Blood samples were collected from BXSB-Yaa mice at 9 weeks of age just before the start of treatment (pre-treatment) and at
20 weeks of age at the conclusion of the study (Post-treatment) and autoantibodies in the plasma were measured using a custom multiplex autoantibody MSD assay (A). The same
multiplex assay was used to measure autoantibodies in plasmas of Pristane DBA/1 mice at 6 months after pristane injection at the conclusion of the study (B). For the pristane-DBA/1
model, mice injected with PBS instead of pristane (Ctl) serve as non-diseased controls. Results presented are a compilation of 2 separate studies and medians are shown.
**Signiﬁcantly different from Veh p b 0.01 or *signiﬁcantly different from Veh p b 0.05 (Kruskal–Wallis, Dunn's).
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the FACS results (Fig. 5A) demonstrating an increase in CD38INTCD138HI
cells with disease and reduction in their numbers with M7583 treat-
ment. Only 4 genes were found changed with disease in the blood of
BXSB-Yaamice. Of note, BCL2A1Awas increasedwith disease and signif-
icantly decreased with Btk inhibition. Previously, BCL2A1 has been
found to be Btk inhibitor responsive in humans after dosing [34] and
after Btk siRNA treatment of human cells in vitro [35]; suggesting
BCL2A1Amay be a useful biomarker for Btk inhibitor activity.
Blood and spleens frommice in pristane-DBA/1 model studies were
also analyzed for gene expression (Fig. 6). In both the blood and spleen
there was a massive induction in expression of interferon-regulated
genes (USP18, IRF7, IFIT1, OAS3) and neutrophil marker genes (MPO,
NGP, C3AR1) with disease. The increase in these genes was not blocked
by compound treatment. Similar to the BXSB-Yaa model, in pristane-DBA/1 mice there was also a decrease in expression of general B cell
marker genes in the spleen (EBF1, MS4A1 (CD20), BANK1, BTK). In the
blood there was not a change in B cell markers, but markers for other
immune cells were altered (i.e. FCGR3, ITGAM, CCR5, PSMB9). BCL2A1A
was again found to be increased with disease and signiﬁcantly affected
by Btk inhibitor treatment. The effect of Btk inhibition on gene expres-
sion in the pristane-DBA/1 model was very minimal and EBF1 in the
blood was the only disease gene that was statistically impacted by
treatment.
To make a quantitative comparison of the levels of IFN in mice from
the two different models, an “IFN gene signature score”was calculated
based on the expression of 5 genes known to be interferon regulated
(USP18, IRF7, IFIT1, OAS3, BST2). A signiﬁcant increase in scores was
found with disease for pristane-DBA/1 mice in both the spleen and
blood (Supplemental Fig. 4). In contrast, there was not an increase in
Fig. 5. FACS analysis of the effect of Btk inhibition on splenocytes. Lupusmicewere treatedwithM7583 (M7583) ormycophenolatemofetil (MMF) via formulated chow and vehicle group
mice were fed normal chow (Veh). Spleens were collected at 20weeks of age from BXSB-Yaamice (A) or at 6months after pristane injection fromDBA/1mice (B). For the pristane-DBA/1
model, mice injectedwith PBS instead of pristane (Ctl) serve as non-diseased controls. Splenocytes were subsequently analyzed by FACS for cell populations and expression of various cell
surface markers. Results shown are a compilation of two separate studies and means ± SEM are presented. **Signiﬁcantly different from Veh p b 0.01 (ANOVA, Dunnett's).
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modest increase in scores in the kidney. The differences in the systemic
expression and magnitude of increase of IFN gene signature scores be-
tween the two models indicates the existence of much higher levels of
circulating interferon in pristane-DBA/1 mice compared to BXSB-Yaa
mice. Clinical studies have found the IFN gene signature in humans to
be relatively stable over time and resistant to change with most treat-
ments, and this seems to be the case in our pristane model studies.
3.6. The effect of Btk inhibition on activation of human immune cells with
SLE relevant stimuli
To better understand the mechanism of action of Btk inhibition in
the two models, and to determine the ability of Btk inhibition to block
FcR activation of myeloid cells, M7583 was tested in vitro using
human immune cells activatedwith representative immune complexes.
First, the ability of Btk inhibition to block activation of IFN production by
anti-RNA binding autoantibodies was tested in PBMCs. When SLE
patient-derived puriﬁed anti-RNP IgG was combined with necrotic celllysate to form immune complexes, it stimulated IFN production (Fig.
7A), presumably through RNA-mediated activation of TLR7 in pDCs
which are recognized as high IFN producing cells in SLE [36]. The stim-
ulatory effect of the immune complexes was abolished by treatment of
the lysate with RNAse, further suggesting that the activation wasmedi-
ated throughRNAactivation of TLR7 (data not shown). The TLR7 agonist
R848 was used as a positive control IFN-inducing stimulus. When
PBMCs were pre-treated with M7583 it was found that Btk inhibition
did not block IFN production (Fig. 7B), except at the 10 μM concentra-
tion, which showed evidence of cell toxicity (data not shown). This
seems to be consistent with the results of the pristane model studies
where the IFN gene signature was not affected by M7583 treatment
(Fig. 6 and Supplemental Fig. 4). To test if Btk inhibition could be reduc-
ing end organ disease in lupus mice through a localized effect, human
monocytes differentiated to macrophages with GM-CSF were used as
a representative myeloid cell type that is activated by pathogenic im-
mune complexes. These cells could be activated to produce TNF-α by
treatment with complexes of IgG-biotin bound to streptavidin beads
(Fig. 7C), which is designed to mimic an immune complex. Btk
Fig. 6.Gene expression analysis of Btk inhibitor treatment of Pristane-DBA/1 and BXSB-Yaamice. Blood and spleenswere collected fromDBA/1mice 6months after pristane injection and
4months of treatmentwithM7583 formulated in chow(M7583) or normal chow(Veh). Blood and spleenswere also collected from age and sexmatchedmice injectedwith PBS instead of
pristane to serve as a healthy control group (Ctl). Blood, spleens, and kidneys were collected from BXSB-Yaamice at 20 weeks of age after treatment with M7583 formulated in chow
(M7583) or normal chow (Veh). The same three tissues were collected from BXSB-Yaamice at 9 weeks of age to serve as a pre-disease control group (Ctl). RNA was isolated and then
analyzed by NanoString for expression of 50 genes. Fold changes for the Veh and M7583 groups relative to the Ctl group were calculated. Shown are heat maps of genes that were
signiﬁcantly changed (p b 0.05 by t-test) with disease (Veh vs Ctl) or with compound treatment (M7583 vs Veh). Results are a compilation of 2 studies and the heat maps show the
fold change for the mean of each group relative to the Ctl group.
74 A.T. Bender et al. / Clinical Immunology 164 (2016) 65–77inhibition with M7583 could block activation of monocyte-derived
macrophages with these complexes and also activation of the cells
with the TLR7 agonist R848 (Fig. 7D). However, the potency for the
compound for blocking these pathways was higher than what was ob-
served with B cell activation. Inhibition of these signaling pathways in
macrophages could explain the efﬁcacy of Btk inhibition in the pristane
model in the absence of an effect on autoantibodies or the IFN gene sig-
nature. Overall, these resultswith human immune cells indicate that Btk
inhibition can block FcR activation inmyeloid cells. Thus, there aremul-
tiple SLE-relevant disease pathways that may be affected by Btk inhibi-
tion and augur beneﬁcial effects for lupus patients of various subsets.
4. Discussion
Btk inhibitors are being developed for treatment of autoimmune dis-
eases as well as hematological cancers dependent on BCR signaling.Ibrutinib was the ﬁrst FDA approved Btk inhibitor and is currently clin-
ically used for treating mantle cell lymphoma and chronic lymphocytic
leukemia. Other Btk inhibitors are currently in development for oncolo-
gy as well as autoimmune indications [3,37]. In our studies we demon-
strated that M7583 is a highly potent and selective Btk inhibitor with a
long duration of action in vivo. Because of these properties, we used the
compound as a tool to determine how inhibition of Btk activity may im-
pact disease in mouse models of lupus and how the preclinical activity
may translate to SLE treatment.
The vast majority of preclinical drug candidate evaluation for lupus
has been performed in the MRL/lpr and NZB/W mouse lupus models
[38,39]. However, with the growing appreciation for the heterogeneity
in lupus has come the recognition that testing candidate therapeutics
in a wider variety of models that mimic different patient populations
may help better predict clinical utility for blocking a pathway or speciﬁc
target. Despite the fact that TLR7 and IFN likely play a role in the disease
Fig. 7. Inhibition of human immune cell activation byM7583. Human immune cells were pre-treatedwithM7583 for 60min prior to activationwith various stimuli designed tomimic FcR
activation. PBMCswere stimulated for 16 hwith complexes of puriﬁed human SLE patient-derived anti-snRNP and necrotic lysate. Supernatants were harvested and assayed for type I IFN
production on a HEK293 interferon stimulated response element (ISRE)-driven luciferase reporter cell line (A). Reporter cells were treated with media alone (No cells), media from
untreated PBMCs (No Stim), R848 (1 μM), the anti-RNP complexes (Stim), and complexes after RNAse treatment. PBMCs were treated with M7583 in different concentrations prior to
anti-RNP complex treatment and activation of IFN reporter cells by their sups was determined (B). Simulation and compound treatment was tested in 4 or more donors in 3 or more
independent experiments. Human monocytes differentiated to macrophages with GM-CSF were activated with either complexes of IgG-biotin-SA-beads or SA-beads combined with a
non-biotinylated IgG (C). Macrophages were also activated with 1 μM R848 (D). TNF-α production was measured after 24 h of macrophage activated by either stimulation.
Macrophage stimulation results show are combined data from 3 separate experiments using 3 different donors for C and 2 experiments with 2 donors for D and presented as
means ± SEM. **Signiﬁcantly different from Veh p b 0.01 or *signiﬁcantly different from Veh p b 0.05 (ANOVA, Dunnett's).
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mouse models that mimic these patients. Thus, we chose to test the ef-
fect of Btk inhibition in the BXSB-Yaa and pristane-DBA/1 models. Prior
studies using genetic knockouts have demonstrated the dependence of
the BXSB-Yaamodel on TLR7 [40,41] and the pristane-DBA/1 model on
both IFN [42,43] and TLR7 [44,45] signaling. These models have not
been used extensively for drug evaluation, although in the pristane
model an anti-IFN antibody [46], an anti-CD80 antibody [47] and several
standard anti-rheumatic agents [48] have demonstrated varying de-
grees of efﬁcacy. The assessment of Btk inhibition in our studies pro-
vides new information on the mechanisms of disease pathogenesis in
these models and further characterizes how they may be used to evalu-
ate candidate drugs. By providing this characterization we hope that
these models will become more useful for others aiming to develop
lupus treatments for this patient population.
We found that blockade of Btk activity with the Btk inhibitor M7583
very effectively treated end-organ disease in both BXSB-Yaa and
pristane-DBA/1 mice as it reduced kidney disease and arthritis respec-
tively in the two models. This is notable as both of these pathologies
are manifested in SLE patients. Although Btk inhibition was therapeutic
in both models, the mechanism of action by which Btk inhibitor treat-
ment provided beneﬁtmay have differed. In the BXSB-Yaamodel Btk in-
hibition resulted in a reduction in nearly all aspects of the disease as
autoantibody titers were decreased, gene expression changes were re-
versed, and the activation of immune cell populations was prevented.
This may indicate an effect on a very proximal aspect of disease patho-
genesis, such as inhibition of BCR activity and autoantibody production.
In contrast, although there was a complete suppression of arthritis in
the pristane-DBA/1 model, there was only a reduction in select autoan-
tibody reactivities and there was no effect on gene expression changes,
particularly for IFN-regulated genes. The disconnect between end organ
efﬁcacy and systemic disease may be explained by an effect of the com-
pound via a different mechanism of action from that in the BXSB-Yaamodel and likely amore localized effect in the diseased paws. However,
we cannot exclude the possibility that the differences are a result of the
treatment in the two models beginning at different phases in the
timecourse of disease as disease may already be more established in
the pristanemodel and B cell activation at a more difﬁcult to treat time.
The pathogenesis of SLE in humans and mice is thought to involve
generation of autoantibodies which form immune complexes that be-
come deposited in tissues and cause inﬂammation and organ damage
[49]. As Btk regulates multiple signaling pathways involved in this pro-
cess, Btk inhibition may provide therapeutic beneﬁt by more than one
mechanism. Btk inhibition could provide beneﬁt by inhibiting BCR acti-
vation and reducing the production of autoantibodies and other B cell
inﬂammatory activities such as cytokine production or presentation of
antigen. This may be the mechanism of action of M7583 treatment in
the BXSB-Yaamodel. Additionally, Btk inhibition may reduce activation
of myeloid cells by immune complexes which bind to Fc receptors. This
inhibition may decrease inﬂammation in tissues where the immune
complexes are deposited and therefore reduce organ damage. This
could explain howM7583 reduces joint arthritis without reducing sev-
eral other upstream disease processes in the pristane-DBA/1 mice. Btk
inhibition may effectively suppress inﬂammation triggered by immune
complexes activating Fc receptors and this hypothesis is supported by
our in vitro studies with macrophages demonstrating the ability of Btk
inhibition to block TNF-α production after treatment with IgG-bead
complexes. However, there may be additional mechanisms by which
Btk inhibition provided beneﬁt, such as through inhibition of TLR signal-
ing. Reports have suggested that Btk regulates toll-like receptor (TLR)
signaling, although some conﬂicting studies exist. Btk has been impli-
cated to play a role in TLR3 [50], TLR4 [51,52], TLR7 [53,54], TLR8 [55]
and TLR9 [53,55] signaling. Additionally, a prior study demonstrated
that Btk is expressed in synovial tissue from RA patients and the Btk in-
hibitor RN486 could block production of some cytokines by RA patient
synovial explants or human macrophages stimulated with IgG-bead
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(complexed with necrotic cell lysate) stimulated IFN production from
PBMCs was not prevented by Btk inhibition. Although both FcR and
TLR7 activation by R848 in macrophages were inhibited by M7583,
there may be differences in regulation of these pathways in pDCs that
leads to IFN production compared to TNF-α production from macro-
phages and thus a differential effect of Btk inhibition between the two
cell types. In support of this hypothesis, Wang et al., have reported
that BTK regulates TLR9 but not TLR7 signaling in human pDCs [57].
Nonetheless, when taken together, the data indicate that by acting
through multiple mechanisms Btk inhibitors may provide beneﬁt to a
wide range of lupus patients.
Given the wide heterogeneity in lupus symptoms and pathogenesis,
a treatment that blocks multiple disease mediating mechanisms would
offer the best chance for providing therapeutic beneﬁt. Btk inhibition
may be a therapeutic approach that can beneﬁt a large proportion of
lupus patients because of its ability to act through several different
mechanisms. The ability of Btk inhibitors to target B cells responsible
for autoantibody production as well as myeloid cells mediating end
organ inﬂammation is a major advantage for this therapeutic approach.
Effectively blocking more than one disease process may provide a high
degree of efﬁcacy, and even if not all disease processes are blocked, ther-
apeutic beneﬁt may still be accomplished if success in only one area is
achieved. This point may be underscored by the efﬁcacy seen with Btk
inhibition in the pristane model and lack of effect of MMF treatment.
MMF (CellCept®), an inhibitor of inosine-5′-monophosphate dehydro-
genase, is a currently used standard of care drug for lupus. MMF mech-
anistically acts as an anti-proliferative against immune cells and has
shown beneﬁt for treatment of lupus patients. In our studies MMF was
nearly as effective in the BXSB-Yaamodel as Btk inhibition. However,
in the pristane-DBA/1 model MMF failed to demonstrate the same
anti-arthritic efﬁcacy as Btk inhibition. As Btk inhibition can affect a
larger number of pathogenic processes, it may have a clinical advantage
over other drugs such as MMF in addition to its greater selectivity.
In summary, the results presented here demonstrate that Btk inhibi-
tion may be an effective therapy for lupus patients with TLR7 and IFN-
driven disease in addition to other lupus subtypes. Furthermore the ef-
ﬁcacy may be achieved through more than one mechanism of action,
making Btk inhibitors a promising therapeutic approach for lupus. Addi-
tionally, these results provide an increased characterization of two
mouse lupus models that may facilitate their use in future candidate
therapeutic studies.
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